NCT Number: NCT06059118
Phase: PHASE2
Trial Summary: Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential trea- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives